| 1. |
- Rodríguez, M, et al.
(författare)
-
Reduction of atherosclerotic nanoplaque formation and size by Ginkgo biloba (EGb 761) in cardiovascular high-risk patients
- 2007
-
Ingår i: Atherosclerosis. - : Elsevier BV. - 0021-9150 .- 1879-1484. ; 192:2, s. 438-444
-
Tidskriftsartikel (refereegranskat)abstract
- Coating a silica surface with the isolated lipoprotein receptor proteoheparan sulfate (HS-PG) from arterial endothelium and vascular matrices and adding both the atherogenic VLDL/IDL/LDL lipid fraction in its native composition and Ca2+ ions, we could observe in vitro the earliest stages of atherosclerotic plaque development by ellipsometric techniques (patent EP 0 946 876). This so-called nanoplaque formation is represented by the ternary aggregational complex of the HS-PG receptor, lipoprotein particles and calcium ions. The model was validated in several clinical studies on statins in cardiovascular high-risk patients. In eight patients who had undergone an aortocoronary bypass operation, the reduction of atherosclerotic nanoplaque formation amounted to 11.9±2.5% (p<0.0078) and of nanoplaque size to 24.4±8.1% (p<0.0234), respectively, after a 2-month therapy with Ginkgo biloba extract (2× 120mg daily, EGb 761). Additionally, superoxide dismutase (SOD) activity was upregulated by 15.7±7.0% (p<0.0391), the quotient oxLDL/LDL lowered by 17.0±5.5% (p<0.0234) and lipoprotein(a) concentration decreased by 23.4±7.9% (p<0.0234) in the patients’ blood. The concentration of the vasodilating substances cAMP and cGMP was augmented by 37.5±9.1% (p<0.0078) and 27.7±8.3% (p<0.0156), respectively. A multiple regression analysis between the patients’ VLDL/IDL/LDL lipoprotein fraction applied in the ellipsometry measurements as well as the further risk factors oxLDL/LDL and Lp(a) on the one hand and changes in nanoplaque formation on the other hand reveals a basis for a mechanistic explanation of nanoplaque reduction under ginkgo treatment. The atherosclerosis inhibiting effect is possibly due to an upregulation in the body's own radical scavenging enzymes and an attenuation of the risk factors oxLDL/LDL and Lp(a).
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Siegel, G., et al.
(författare)
-
Ginkgo biloba and its Influence on Nanoplaque Formation and Vascular Function
- 2008
-
Ingår i: Diabetes stoffwechsel und herz. - 1861-7603. ; 17, s. S23-S35
-
Tidskriftsartikel (refereegranskat)abstract
- Background: In a pilot study, we demonstrated the beneficial effects of Ginkgo biloba (EGb 761) on atherosclerotic nanoplaque formation and size, the oxLDL/LDL quotient and the lipoprotein(a) concentration, the increase in superoxide dismutase activity, as well as the cAMP and cGMP concentrations. Method: The measurable variables formerly used were supplemented by a biomarker spectrum, through which the latest parameter and markers of plaque stability and progression, oxidative stress, and inflammation could be determined. Results: In 11 patients with early-stage metabolic syndrome, atherosclerotic nanoplaque formation fell by 14.3 +/- 2.9 (p < 0.0077) and nanoplaque size by 23.4 +/- 3.7 % (p < 0.0004), respectively, after a two-month regime with Ginkgo biloba extract. Superoxide dismutase and glutathione peroxidase (GPx) activities were upregulated by 19.6 +/- 10.0 % (p < 0.0785) and 11.6 +/- 2.3 % (p < 0.001), respectively. The quotient oxLDL/LDL fell by 21.0 +/- 4.3 % (p < 0.002), and lipoprotein(a) concentration by 26.3 t 4.8 % (p < 0.001). The concentrations of cAMP and cGMP were augmented by43.5 12.0% (p < 0.001)and 32.9 +/- 10.4% (p < 0.001), respectively. The serum Call concentration fell by 5.4 +/- 1.6 % (p < 0.0076). We could also show a favourable development of 8-iso-PGF(2 alpha), oxLDL/LDL, SOD, GPx, hsCRP MPO,TNF alpha, TGF beta(1), and MMP-9. Conclusion: Ginkgo with its pleiotropic effects should be assigned a fixed rank among the anti-ageing medical therapeutics.
|
|
